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ABSTRACT
Objectives Reproductive tract infections (RTIs),
including sexually acquired, among adolescent girls is a
public health concern, but few studies have measured
prevalence in low-middle-income countries. The objective
of this study was to examine prevalence in rural
schoolgirls in Kenya against their reported symptoms.
Methods In 2013, a survey was conducted in 542
adolescent schoolgirls aged 14–17 years who were
enrolled in a menstrual feasibility study. Vaginal self-
swabbing was conducted after girls were interviewed
face-to-face by trained nurses on symptoms. The
prevalence of girls with symptoms and laboratory-
conﬁrmed infections, and the sensitivity, speciﬁcity,
positive and negative predictive values of symptoms
compared with laboratory results, were calculated.
Results Of 515 girls agreeing to self-swab, 510
answered symptom questions. A quarter (24%) reported
one or more symptoms; most commonly vaginal
discharge (11%), pain (9%) or itching (4%). Laboratory
tests conﬁrmed 28% of girls had one or more RTI.
Prevalence rose with age; among girls aged 16–
17 years, 33% had infections. Bacterial vaginosis was
the most common (18%), followed by Candida albicans
(9%), Chlamydia trachomatis (3%), Trichomonas
vaginalis (3%) and Neisseria gonorrhoeae (1%).
Reported symptoms had a low sensitivity and positive
predictive value. Three-quarters of girls with bacterial
vaginosis and C. albicans, and 50% with T. vaginalis
were asymptomatic.
Conclusions There is a high prevalence of adolescent
schoolgirls with RTI in rural Kenya. Public efforts are
required to identify and treat infections among girls to
reduce longer-term sequelae but poor reliability of
symptom reporting minimises utility of symptom-based
diagnosis in this population.
Trial registration number ISRCTN17486946.
INTRODUCTION
An estimated half a billion new cases of curable
sexually transmitted infections occur each year glo-
bally,1 2 with women being more susceptible and
bearing the greatest burden of these infections.
Reproductive tract infections (RTIs), including
those sexually acquired, have historically been
labelled a ‘silent’ epidemic among females,
contributing to gynaecological morbidity and
maternal mortality globally, including
low-middle-income countries (LMICs).1 Untreated
infections can lead to pelvic inﬂammatory diseases,
ectopic pregnancy, infertility, cervical cancer, foetal
loss or infant health complications, with a threefold
to ﬁvefold increase in risk of HIV acquisition and
transmission.1 w1 Bacterial vaginosis is associated
with increased risk for acquisition of HIV,3 w2 pro-
motes viral shedding among HIV-infected females4
and increases susceptibility for other infections
such as gonorrhoea, trichomoniasis and herpes
simplex virus type-2 (HSV-2).5–8 w3 Adolescent
females are vulnerable to bacterial vaginosis infec-
tion,1 w4 with an association between human papil-
lomavirus infection, bacterial vaginosis and
cervicitis.9 This is compounded by adolescent girls’
heightened susceptibility to HIV, for biological as
well as socio-cultural reasons,10 in western Kenya,
for example, young females have a sixfold greater
risk of contracting HIV compared with young
males.11
Although research on the burden of RTI among
adolescent females in LMIC is limited, WHO esti-
mates 80–90% of the global burden lies in
LMICs.1 In Kenya, one in every ﬁve youths 15–
24 years report sexual debut before the age of
15 years.w5 While HIV prevalence has fallen
nationally, it remains static in rural parts of the
former Nyanza Provincew5 and rises among girls
during adolescence.11 For the region, RTI preva-
lence is also high, with a third of urban adolescent
girls aged 15–19 years diagnosed with Trichomonas
vaginalis,12 and a smaller proportion with other
infections (9% Chlamydia trachomatis; 2%
Neisseria gonorrhoeae, 3% syphilis).13 However,
data are sparse on the prevalence of RTI among
post-pubescent girls in rural African settings.
Symptom assessment has commonly been used
to prescribe treatment of RTI, and a simpliﬁed
algorithm to guide health workers in the imple-
mentation of syndromic management of RTI has
been developed.14 w6 This was intended to deﬁne
cause among the symptomatic rather than as a
screening tool in the general population. Experts
advocate supplementary point-of-care testing
because of the poor predictive value of symptoms
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alone.15 Symptom guidelines at the national level have also been
questioned in western Kenya when compared with laboratory
diagnosis.w7 While menstrual studies among adolescent girls
describe a high prevalence of RTI, seemingly due to poor hygie-
ne,w8 most relied on reported symptoms.16 However, a study
among women found symptom-based reporting was higher than
laboratory-conﬁrmed RTIs illustrating again the limitation of
symptom reporting.16 The objective of this study was to
measure the prevalence of RTI among adolescent schoolgirls in
a menstrual feasibility study in rural western Kenya and to calcu-
late the predictive value of girls’ symptom-based reporting
against laboratory-conﬁrmed infections.
METHODS
Study setting
The population under study are resident in the Kenyan Medical
Research Institute (KEMRI) and Centers for Disease Control
and Prevention’s health and demographic surveillance system
(HDSS),w9 in Gem subcounty, Siaya County, western Kenya.
This rural population are almost exclusively comprised of the
Luo ethnic group who are mainly farmers.w9
Study design
Cross-sectional, laboratory-supported, RTI survey nested within
a menstrual feasibility study.
Menstrual feasibility study
The ‘parent’ study, conducted August 2012 to November 2013,
was a randomised controlled pilot examining the feasibility of
menstrual solutions for girls in rural primary schools in western
Kenya. In total, 30 of 62 schools participating in a baseline
water, sanitation and hygiene survey reached eligibility for par-
ticipation.17 No schools withdrew. All girls in study schools
were enrolled if resident in the study area, were aged 14–
16 years at enrolment, in classes 5–8, had no debilitation pre-
cluding participation and had experienced three or more
menses. We estimated 669 participants followed to outcome
provided 76% power to detect a 50% reduction in outcome
(dropout), with an intra-cluster correlation coefﬁcient of 0.01
and design effect of 1.21. Of 1005 target girls screened, 766
were enrolled and 40 (4%) refused, with the remaining 199
ineligible. Of the 766, 542 were in school for the cross-sectional
RTI survey conducted in November 2013. Attrition (224 girls;
29.2%) prior to the RTI survey was due to withdrawal (2.1%),
migration (12.4%), dropout (7.9%) and participants in class 8
exiting after their exams in October (6.8%).
RTI cross-sectional survey methods
Study nurses, trained by a gynaecologist, privately questioned
participants on a list of RTI-associated signs and symptoms
before sample collection (see online supplementary form S1).
All survey tools were pilot tested and nurses explained symp-
toms when interviewing. Symptoms covered urinary complaints,
pain or bleed during sexual intercourse, vaginal discharge, mal-
odorous or ﬁshy smell, genital itching/irritation, lower abdom-
inal or vaginal pain or both, and abnormal bleeding (heavy or
between periods).14 w6 w10
Nurses trained participants to obtain their own vaginal
swab.18 Samples were transported daily to the KEMRI labora-
tory, prepared and analysed for Candida albicans, bacterial
vaginosis, T. vaginalis, C. trachomatis and N. gonorrhoeae using
standard methods.w11 Bacterial vaginosis was deﬁned as a
Nugent Score of 7–10. Girls with a laboratory-conﬁrmed
diagnosis were treated by study nurses according to Kenyan
national guidelines.
Statistical analysis
Laboratory-conﬁrmed infections were the measured outcome,
and signs and symptoms the predictor variables, with age, socio-
economic status (SES), age at menarche and prior use of sanitary
pads also assessed as potential confounders. Data on SES were
missing for 78 participants and were excluded from speciﬁc
SES-related analysis. The prevalence of girls with individual
infections and the 95% CI were calculated, then aggregated into
all RTI. The prevalence of girls reporting symptoms were calcu-
lated, then aggregated into any symptom reported. Girls’ ages
were collapsed into younger (<16 years) and older (>16 years)
age groups. SES of participants was available from routine
household surveys in the HDSS,w9 dichotomising quintiles into
the poorest (1–2) and least poor (3–5). Differences due to age,
SES, age of menarche and any prior sanitary pad use were
assessed using Pearson’s χ2 test. The sensitivity, speciﬁcity, posi-
tive predictive value (PPV) and negative predictive value (NPV)
of symptoms alone, and then pooled, were computed for pre-
dicting each laboratory-conﬁrmed (gold standard) infection,
along with their 95% CI. Data analysis was performed using
SPSS v.21.0.
RESULTS
Of 542 adolescent schoolgirls present in school and approached
for this study, 515 (95%) participated in the vaginal swabbing;
25 declined saying they were menstruating (including at a
second follow-up) and 2 refused. Age at survey ranged from 14
to 17 years, with a mean of 15.2 years (SD 0.6 year).
Participants’ median SES index was 4 (range 1–5), with 17%
falling into the poorest two quintiles. Girls’ mean age of menar-
che was 13.6 years (SD 0.9 year), with 83.5% reporting some
prior use of sanitary pads. Less than 1% of girls reported they
were currently sexually active (past month), while 46 (9%)
answered the question on symptoms occurring during sex. Of
515 girls who self-swabbed for laboratory conﬁrmation of RTI
diagnoses, 510 (99%) answered questions on symptoms.
A quarter of participants reported one or more symptoms
(table 1). Most common among these was vaginal discharge, fol-
lowed by pain or itching. There was no difference in overall
symptoms reported by age, SES, age at menarche or prior use of
sanitary pads. However, younger (<16 years) girls were twofold
less likely to report vaginal discharge than girls aged >16 years
(p=0.002; table 1). Overlapping of symptoms was common,
with two-thirds of girls reporting two or more symptoms in
addition to itching or sore vagina, malodorous smell, burning
urine or bleeding between menses (see online supplementary
table S2).
Laboratory tests conﬁrmed 28% of participants had at least
one RTI, with bacterial vaginosis the most common diagnosis
among 18% of girls (table 2). T. vaginalis was threefold higher
in older compared with younger girls (p=0.03). A higher pro-
portion of girls in the poorest SES quintiles were diagnosed
with bacterial vaginosis or C. albicans (p=0.076).
Three-quarters of girls with bacterial vaginosis and C. albicans
infections were asymptomatic, with slightly higher proportions
of girls with T. vaginalis, C. trachomatis and N. gonorrhoeae
reporting at least one symptom (table 3). In the analysis of sensi-
tivity and PPV, between girls’ reporting symptoms and
laboratory-conﬁrmed bacterial vaginosis, malodorous smell
achieved a PPV >50%, while vaginal itching was 32%. There
was a low sensitivity and PPV for girls’ reporting symptoms
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associated with C. trachomatis. Pain or bleed during intercourse
was predictive for T. vaginalis among the few infected girls
acknowledging sexual intercourse. The low prevalence of girls
with N. gonorrhoeae (<1%) limited analysis. Burning urine had a
low PPV (table 3).
DISCUSSION
This study demonstrates over a quarter of young adolescent
schoolgirls in a rural African setting had a laboratory-diagnosed
RTI. One-third of older aged (16–17 years) girls were infected.
The largest contribution to the infection pool was from bacterial
vaginosis. The predictive value of reported symptoms was gen-
erally very low. Despite this, there remains inadequate data on
laboratory-conﬁrmed cases of RTI among school-aged girls in
Africa.
This study was nested in a cluster randomised controlled pilot
study examining the feasibility of girls’ use of menstrual care
products in schools. Sampling bias may have occurred as schools
have been shown to be protective against sexual infections such
as HIV,19 20 resulting in a lower prevalence of RTI than among
non-attending adolescent girls. We acknowledge use of some
menstrual items may have potentially reduced some girls’ expos-
ure to RTI,16 21 with outcomes on the effect of different pro-
ducts currently under evaluation. While a high reliability of
self-obtained swabs for RTI diagnosis has been demonstrated
elsewhere,18 w12 we note girls in our endline focus groups
reported a minority of their peers avoided swabbing by spitting
on the swabs. Such swabs were processed in the denominator
and would have also possibly lowered the prevalence of girls
with detected infections. Less than 1% of girls said they had
sexual intercourse in the past month, and 9% answered a ques-
tion on symptoms occurring during sex at face-to-face interview.
This is an underestimate, as in a private self-completed survey
28% reported sexual exposure (unpublished). Studies in Kenya
and Tanzania estimated up to a threefold higher prevalence of
sexual exposure (including coerced) when girls self-completed
surveys, for example, by computer.22 w13 No clinical examin-
ation of individuals was conducted, thus, the presence of a
lesion (ulcer) relied on girls’ reporting an itchy/sore vagina. We
cannot rule out that girls when faced with intimate questions
about vaginal discharge or pain may have been too embarrassed,
or too scared, to disclose symptoms face-to-face in the nurses’
interview.23 They may also be less familiar with their bodily
‘norm’ so symptoms may have gone unnoticed. Moreover, due
to ﬁnancial constraints, examination of other RTI such as syph-
ilis and HSV-2 was not possible and we recommend that studies
include these also to ensure comprehensive mapping of infec-
tion, and healthcare needs of adolescent girls.
Synonymous with our ﬁndings, a study conducted in South
Africa reported symptomatic vaginal discharge among high-risk
girls and women was a poor predictor of RTI and genital tract
inﬂammation (sensitivity of 12.3% and speciﬁcity of 93.8%),
with 87.7% of laboratory-diagnosed infections having no
accompanying clinical symptoms.24 Similarly, a study in
Botswana reported three-quarters of pregnant women attending
antenatal clinics were asymptomatic.25 Syndromic management
failed to capture half of women with T. vaginalis or bacterial
vaginosis infections during antenatal care, leading to signiﬁcant
Table 1 Prevalence of girls with reported symptoms by age group at survey
Prevalence (95% CIs) of girls with reported symptoms Age comparison
14–15 years 16–17 years Total Ratios χ2, p value
370 140 510*
Any symptom 82/370 22.2 (18.0 to 26.4) 40/140 28.6 (21.1 to 36.1) 122/510 23.9 (20.2 to 27.6) 0.78 (0.56 to 1.07) 2.29; 0.13
Heavy menstruation 25/370 6.8 (4.3 to 9.4) 8/140 5.7 (1.9 to 9.5) 33/510 6.5 (4.4 to 8.6) 1.18 (0.55 to 2.56) 0.18; 0.67
Between menses bleeding 15/370 4.1 (2.1 to 6.1) 5/140 3.6 (0.5 to 6.7) 20/510 3.9 (2.2 to 5.6) 1.14 (0.42 to 3.07) 0.06; 0.80
Burning urine 9/370 2.4 (0.8 to 4.0) 2/140 1.4 (−0.6 to 3.4) 11/510 2.2 (0.9 to 3.5) 1.70 (0.37 to 7.78) 0.49; 0.49
Frequency of urine 11/370 3.0 (1.3 to 4.7) 2/140 1.4 (−0.6 to 3.4) 13/510 2.5 (1.2 to 3.9) 2.08 (0.47 to 9.27) 0.98; 0.32
Abdominal/vaginal pain 30/370 8.1 (5.3 to 10.9) 15/140 10.7 (5.6 to 15.8) 45/510 8.8 (6.3 to 11.3) 0.76 (0.42 to 1.36) 0.86; 0.35
Pain during intercourse† 1/35 2.9 (−2.7 to 8.5) 1/11 9.1 (−7.9 to 26.1) 2/46 4.3 (−1.6 to 10.2) 0.31 (0.02to 4.62) 0.78; 0.38
Itchy/sore vagina‡ 16/365 4.4 (2.3 to 6.5) 6/139 4.3 (0.9 to 7.7) 32/504 4.4 (2.6 to 6.2) 1.02 (0.41 to 2.54) 0.001; 0.94
Malodorous smell 5/364 1.4 (0.2 to 2.6) 4/139 2.9 (0.1 to 5.7) 9/503 1.8 (0.6 to 3.0) 0.48 (0.13 to 1.75) 1.3; 0.26
Vaginal discharge 29/367 7.9 (5.1 to 10.7) 34/139 17.3 (11.0 to 23.6) 53/506 10.5 (7.8 to 13.2) 0.46 (0.28 to 0.76) 9.4; 0.002
*Five participants reporting ‘don’t know’ for all symptoms are excluded.
†Sample limited to girls responding to symptoms of pain or bleeding during sexual intercourse (n=46).
‡4–6 girls did not answer questions on vaginal itching, smell and discharge.
Table 2 Prevalence of girls with laboratory-confirmed infections by age group
Prevalence (95% CIs) of girls with laboratory diagnoses* Age comparison
14–15 years 16–17 years Total Ratios χ2, p value
Bacterial vaginosis 61/374 16.3 (12.2 to 20.4) 33/141 1.12 (0.58 to 2.15) 94/515 18.3 (14.6 to 22.0) 0.70 (0.48 to 1.02) 3.45; 0.06
Candida albicans 33/373 8.8 (5.8 to 11.8) 11/139 0.75 (0.56 to 1.02) 44/512 8.6 (6.1 to 11.1) 1.12 (0.58 to 2.15) 0.11; 0.74
Chlamydia trachomatis 10/371 2.7 (1.1 to 4.4) 3/140 0.32 (0.11 to 0.93) 13/511 2.5 (1.2 to 3.9) 1.26 (0.35 to 4.50) 0.13; 0.73
Trichomonas vaginalis 6/373 1.6 (0.3 to 2.9) 7/139 0.76 (0.07 to 8.26) 13/512 2.5 (1.2 to 3.9) 0.32 (0.11 to 0.93) 4.81; 0.03
Neisseria gonorrhoeae 2/371 0.5 (−0.2 to 1.2) 1/140 0.55 (0.26 to 1.15) 3/511 0.6 (−0.1 to 1.3) 0.76 (0.07 to 8.26) 0.5; 0.82
All reproductive tract infections 98/374 26.2 (21.7 to 30.7) 47/141 0.70 (0.48 to 1.02) 145/515 28.2 (24.3 to 32.1) 0.79 (0.59 to 1.05) 2.57; 0.11
*2–4 tests spoiled.
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Table 3 Disease prediction of symptoms against laboratory diagnosis (95% CI) of reproductive tract infections
Sensitivity Specificity PPV NPV
n % (95% CI) n % (95% CI) N % (95% CI) n % (95% CI)
Bacterial vaginosis
Heavy menstruation 7/93 7.5 (3.1 to 14.9) 391/417 93.8 (91.0 to 95.9) 7/33 21.2 (9.0 to 38.9) 391/477 82.0 (78.2 to 85.3)
Between menses bleeding 4/93 4.3 (1.2 to 11.0) 401/417 96.2 (93.8 to 97.8) 4/20 20.0 (5.7 to 43.7) 401/490 81.8 (78.1 to 85.2)
Burning urine 2/93 2.2 (0.3 to 7.6) 408/417 97.8 (95.9 to 99.0) 2/11 18.2 (2.3 to 51.8) 408/499 81.8 (78.1 to 85.1)
Frequency of urine 4/93 4.2 (1.2 to 10.4) 408/417 97.8 (95.9 to 99.0) 4/13 30.8 (9.1 to 61.4) 408/497 82.1(78.2 to 85.3)
Abdominal/vaginal pain 10/93 10.7 (5.3 to 18.9) 382/417 91.6 (88.5 to 94.1) 10/45 22.2 (11.2 to 37.1) 382/465 82.2 (78.4 to 85.5)
Pain during intercourse* 1/6 16.7 (0.5 to 64.1) 39/40 97.5 (86.4 to 99.9) 1/2 50.0 (1.3 to 98.7) 39/44 88.6 (75.4 to 96.2)
Itchy/sore vagina† 7/92 7.6 (3.1 to 15.1) 397/412 96.4 (94.1 to 98.0) 7/22 31.8 (13.9 to 54.9) 397/482 82.4 (78.7 to 85.7)
Malodorous smell 5/91 5.5 (1.8 to 12.4) 408/412 99.0 (97.5 to 99.7) 5/9 55.6 (21.2 to 86.3) 408/494 82.6 (79.0 to 85.8)
Vaginal discharge 11/93 11.8 (6.1 to 20.2) 371/413 89.8 (86.5 to 92.6) 11/53 20.8 (10.8 to 34.1) 371/453 81.9 (78.0 to 85.3)
Any symptoms 26/93 28.0 (19.1 to 38.2) 321/417 77.0 (72.6 to 80.9) 26/122 21.3 (15.0 to 29.7) 321/388 82.7 (78.6 to 86.4)
Candida albicans
Heavy menstruation 4/44 9.1 (2.5 to 21.7) 435/463 94.0 (91.4 to 95.9) 4/32 12.5 (3.5 to 29.0) 435/475 91.6 (88.7 to 93.9)
Between menses bleeding 1/44 2.2 (0.1 to 12.0) 444/563 95.9 (93.7 to 97.5) 1/20 5.0 (0.1 to24.9) 444/487 91.2 (88.3 to 93.5)
Burning urine 0/44 0.0 (0.0 to 8.4) 452/463 97.6 (95.8 to 98.8) 0/11 0.0 (0.0 to 28.5) 452/496 91.1 (88.3 to 93.5)
Frequency of urine 0/44 0.0 (0.0 to 8.0) 451/463 97.4 (95.5 to 98.7) 0/12 0.0 (0.0 to 26.5) 451/495 91.1 (88.3 to 93.5)
Abdominal/vaginal pain 6/44 13.6 (5.2 to 27.9) 424/463 91.6(88.7 to 93.9) 6/45 13.3 (5.5 to 26.8) 424/462 91.8 (88.9 to 94.1)
Pain during intercourse 0/8 0.0 (0.0 to 36.9) 36/38 94.7 (82.3 to 99.4) 0/2 0.0 (0.0 to 84.2) 36/44 81.8 (67.3 to 91.8)
Itchy/sore vagina 1/44 2.3 (0.1 to 12.0) 437/457 95.6 (93.3 to 97.3) 1/21 4.8 (0.1 to 23.8) 437/480 91.0 (88.1 to 93.4)
Malodorous smell 0/42 0.0 (0.0 to 8.4) 450/458 98.3 (96.6 to 99.2) 0/8 0.0 (0.0 to 36.9) 450/492 91.5 (88.6 to 93.8)
Vaginal discharge 3/43 7.0 (1.4 to 19.1) 410/460 89.1 (85.9 to 91.8) 3/53 5.7 (1.2 to 15.7) 410/450 91.1 (88.1 to 93.6)
Any symptoms 11/44 25.0 (13.2 to 40.3) 354/463 76.5 (72.3 to 80.3) 11/120 9.2 (4.7 to 15.8) 354/387 91.1 (88.2 to 94.1)
Chlamydia trachomatis
Heavy menstruation 0/13 0.0 (0.0 to 24.7) 461/494 93.3 (90.6 to 95.4) 0/33 0.0 (0.0 to 10.6) 461/474 97.3 (95.4 to 98.5)
Between menses bleeding 0/13 0.0 (0.0 to 24.7) 475/494 96.2 (94.1 to 97.7) 0/19 0.0 (0.0 to 17.7) 475/488 97.3 (95.5 to 98.6)
Burning urine 1/13 7.7 (0.2 to 36.0) 484/494 98.0 (96.3 to 99.0) 1/11 9.1 (0.2 to 41.3) 484/496 97.6 (95.8 to 98.8)
Frequency of urine 0/13 0.0 (0.0 to 24.7) 481/494 97.4 (95.5 to 98.6) 0/13 0.0 (0.0 to 24.7) 481/494 97.4 (95.5 to 98.6)
Abdominal/vaginal pain 2/13 15.4 (1.9 to 45.5) 451/494 91.3 (88.5 to 93.6) 2/45 4.4 (0.5 to 15.2) 451/462 97.6 (95.8 to 98.8)
Pain during intercourse 0/1 0.0 (0.0 to 97.5) 43/45 95.6 (84.9 to 99.5) 0/2 0.0 (0.0 to 84.2) 43/44 97.7 (88.0 to 99.9)
Itchy/sore vagina 1/13 7.7 (0.2 to 36.0) 467/488 95.7 (93.5 to 97.3) 1/22 4.6 (0.1 to 22.8) 467/479 97.5 (95.7 to 98.7)
Malodorous smell 0/13 0.0 (0.0 to 24.7) 478/487 98.2 (96.5 to 99.2) 0/9 0.0 (0.0 to 33.6) 478/491 97.4 (95.5 to 98.6)
Vaginal discharge 2/13 15.4 (1.9 to 45.5) 439/490 89.6 (86.5 to 92.2) 2/53 3.8 (0.5 to 13.0) 439/450 97.6 (95.7 to 98.8)
Any symptoms 4/13 30.8 (9.1 to 61.4) 377/494 76.3 (72.3 to 80.0) 4/121 3.3 (0.9 to 8.3) 377/386 97.7 (95.6 to 98.9)
Trichomonas vaginalis
Heavy menstruation 1/12 8.3 (0.2 to 38.5) 464/495 93.4 (90.8 to 95.4) 1/32 2.9 (0.1 to 15.3) 464/475 97.7 (95.9 to 98.8)
Between menses bleeding 0/12 0.0 (0.0 to 26.5) 475/495 96.0 (93.8 to 97.5) 0/20 0.0 (0.0 to 16.8) 475/487 97.5 (95.7 to 98.7)
Burning urine 1/12 8.3 (0.2 to 38.5) 485/495 98.0 (96.3 to 99.0) 1/11 9.1 (0.2 to 41.3) 485/496 97.8 (96.1 to 98.9)
Frequency of urine 0/12 0.0 (0.0 to 26.5) 483/495 97.6 (95.8 to 98.7) 0/12 0.0 (0.0 to 26.5) 483/495 97.6 (95.8 to 98.7)
Abdominal/vaginal pain 2/12 16.7 (2.1 to 48.4) 452/495 91.3 (88.5 to 93.6) 2/45 4.4 (0.5 to 15.2) 452/462 97.8 (96.1 to 99.0)
Pain during intercourse 2/2 100 (15.8 to 100) 44/44 100 (92.0 to 100) 2/2 100 (15.8 to 100) 44/44 100 (92.0 to 100)
Itchy/sore vagina 1/12 8.3 (0.2 to 38.5) 469/489 95.9 (93.8 to 97.5) 1/21 4.8 (0.1 to 23.8) 469/480 97.7 (95.9 to 98.9)
Malodorous smell 2/12 16.7 (2.1 to 48.4) 482/488 98.8 (97.3 to 100) 2/8 25.0 (3.2 to 65.1) 482/492 98.0 (96.3 to 100)
Vaginal discharge 2/12 16.7 (2.1 to 48.4) 440/491 89.6 (86.6 to 92.2) 2/53 3.8 (0.5 to 13.0) 440/450 97.8 (96.0 to 98.9)
Any symptoms 6/12 50.0 (21.1 to 78.9) 381/495 77.0 (73.0 to 80.6) 6/120 5.0 (1.9 to 10.6) 381/387 98.5 (96.7 to 99.4)
Neisseria gonorrhoeae*
Heavy menstruation 1/3 33.3 (0.8 to 90.6) 472/504 93.7 (91.2 to 95.6) 1/33 3.0 (0.1 to 15.8) 472/474 99.6 (98.5 to 100)
Between menses bleeding 1/3 33.3 (0.8 to 90.6) 486/504 96.4 (94.4 to 97.9) 1/19 5.3 (0.1 to 26.0) 486/488 99.6 (98.5 to 100)
Burning urine 1/3 33.3 (0.8 to 90.6) 494/504 98.2 (96.4 to 99.0) 1/11 9.1 (0.2 to 41.3) 494/496 99.6 (98.6 to 100)
Frequency of urine 0/3 0.0 (0.0 to 70.6) 491/504 97.4 (95.6 to 98.6) 0/13 0.0 (0.0 to 24.7) 491/494 99.4 (98.6 to 99.9)
Abdominal/vaginal pain 1/3 33.3 (0.8 to 90.6) 460/504 91.3 (88.5 to 93.6) 1/45 2.2 (0.1 to 11.8) 460/462 99.6 (98.5 to 100)
Itchy/sore vagina 1/3 33.3 (0.8 to 90.6) 477/498 95.8 (93.6 to 97.4) 1/22 4.6 (0.1 to 22.8) 477/479 99.6 (98.5 to 100)
Malodorous smell 0/3 0.0 (0.0 to 70.7) 488/497 98.2 (96.6 to 99.1) 0/9 0.0 (0.0 to 33.6) 488/491 99.4 (98.2 to 100)
Vaginal discharge 1/3 33.3 (0.8 to 90.6) 448/500 89.6 (86.6 to 92.1) 1/53 1.9 (0.1 to 10.1) 448/450 99.6 (98.4 to 100)
Any symptoms 2/3 66.7 (9.4 to 99.1) 385/504 76.4 (72.3 to 80.0) 2/121 1.9 (0.2 to 5.8) 385/386 99.7 (98.6 to 100)
*Pain or bleed during intercourse was limited to 46 girls responding to symptoms of pain or bleeding during sexual intercourse (no data for N. gonorrhoeae).
†4–6 girls did not answer questions on vaginal itching, smell, discharge.
NPV, negative predictive value; PPV, positive predictive value.
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challenges for diagnosis and treatment among this critically vul-
nerable group.25 Adding to the evidence from South Africa26
and Botswana,25 27 our data suggest that the syndromic
approach is not a good enough indicator of RTI, and new
approaches are needed.
A study among African females found a high prevalence of
bacterial vaginosis was associated with recent unprotected
sexual intercourse.26 Among adolescent girls from South Africa
and Kenya, 16–17-year-old sexually active girls reported
minimal symptoms (2/60; 3.3%) while the prevalence of
laboratory-conﬁrmed RTI was very high (in 60 girls, 23 were
diagnosed with bacterial vaginosis, 12 with C. albicans, 4 with
T. vaginalis and 4 with C. trachomatis).26 28 w14
The relationship between bacterial vaginosis, N. gonorrhoeae,
C. trachomatis and genital ulcer disease, and the increase in the
risk of HIV transmission,3 5–8 w2–3 makes early detection and
diagnosis of RTI a major public health imperative.2 w15 Studies
in western Kenya among the Luo show a rapid rise in HIV and
HSV-2 prevalence during adolescence among girls,11 suggesting
that many of our schoolgirls not already infected with HIV are
at further risk of acquiring HIV due to their RTI-infected status.
A reduction in prevalence is possible, for example, in Tanzania
in areas where women had improved access to laboratory diag-
nosis and treatment of RTIs, incident HIV infections were
reduced by 40%.29 T. vaginalis infection is a common curable
sexually transmitted infection with high prevalences observed in
the African subcontinent.2 However, this vaginal condition may
cause substantial morbidity among women in developing coun-
tries if untreated. No comparison study was available among
adolescents; however, among pregnant women in Botswana, T.
vaginalis was found in 19% and bacterial vaginosis in 38% of
the study participants.25 Unless drastic measures are put into
place, the high prevalence of infections found in young adoles-
cent girls is likely to remain undetected and untreated, leading
to a rising pool of infection in the local population, increasing
morbidity and reducing their fertility, as well as increasing their
risk of other RTI and HIV.
From our data, we have identiﬁed three priority areas for
public health intervention among this female adolescent popula-
tion. First, girls need to learn self-awareness of their own bodies
to be able to recognise any changes in order that symptoms are
detected as being different from their normal state. Second, girls
need to understand that it is possible to have an RTI despite
having no symptoms. Third, methods to achieve prevention
must be made readily available to adolescent girls. Our data,
combined with other ﬁndings, point to the urgent need for
sexual and reproductive health education, including a focus on
personal hygiene, combined with the provision of friendly
sexual and reproductive health services including treatment and
counselling services. The latter must be easily accessible to girls
who have little free time and no resources to travel. Without
such interventions, it is difﬁcult to envisage any real progress in
reducing the prevalence of RTI, poor maternal health outcomes
and HIV acquisition.3 w15 One solution, in part, may be school-
based,30 through school nurses who, as well as treating and
referring girls to specialist services, could educate and counsel
girls as they reach menarche and become sexually active.
In summary, our study adds to a sparse body of literature,
showing a high prevalence of RTI among school-aged girls in a
rural African setting. The majority of infections were asymptom-
atic, demonstrating a very poor sensitivity of symptom-based
reporting. The use of syndromic management to reduce RTI
and HIV incidence in this adolescent population would leave
most of these very vulnerable girls untreated (even if they would
present to a health clinic). Technological advancements that can
enable quick, easy and cost-effective diagnosis of RTIs may be a
desirable step towards realising effective management of repro-
ductive health in rural African settings.
Key messages
▸ Adolescent schoolgirls in rural Kenya have a high prevalence
of reproductive tract infections.
▸ Symptom-based reporting has a poor sensitivity missing
three-quarters of laboratory-conﬁrmed infections.
▸ Greater public health efforts are required to diagnose and
treat infections among vulnerable girls to minimise
long-term sequelae.
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